A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain

Phase 3 Completed 89 enrolled Kissei Pharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Multi-center, randomized, double-blind, parallel-group study to confirm superiority of KLH-2109 to placebo in uterine fibroids patient with menorrhagia and pain

Timeline

Start: 2022-10-11
Primary completion: 2024-02-16
Completion: 2024-02-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	KLH-2109	Unknown	—	Oral

A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain

Summary

Timeline

Drugs

Indications